Exploring HPV vaccination policy and payer strategies for opportunities to improve uptake in safety-net settings

Dados Bibliográficos

ID22091841
AutoresKylie Sloan (University of Southern California), Michelle Shin (0000-0002-5022-3566, University of Southern California), Lawrence A Palinkas (0000-0003-0974-7330, University of Southern California), Shawna V Hudson (0000-0002-7026-0743, Rutgers, the State University of New Jersey), Benjamin F Crabtree (0000-0003-2292-6835, Rutgers, the State University of New Jersey), Joel C Cantor (0000-0003-0786-3258, Rutgers, the State University of New Jersey), Jennifer Tsui (0000-0002-5616-9636, University of Southern California, autor correspondente)
Ano2023
Volume11
Páginas1099552-1099552
Data de publicação2023-05-04
Peer ReviewedSim
Open AccessSim
TipoARTICLE
PeriódicoFrontiers in Public Health (JOURNAL)
Identificadores do periódicoISSN: 2296-2565 • E-ISSN: 2296-2565
EditoraFrontiers Media SA (PUBLISHER • CH)
DOI10.3389/fpubh.2023.1099552
PMID37213634
OpenAlexW4368368227
IdiomaEN
Citações recebidas2
Referências citadas30

Introduction: We explored priorities and perspectives on health policy and payer strategies for improving HPV vaccination rates in safety-net settings in the United States. Methods: We conducted qualitative interviews with policy and payer representatives in the greater Los Angeles region and state of New Jersey between December 2020 and January 2022. Practice Change Model domains guided data collection, thematic analysis, and interpretation. Results: Five themes emerged from interviews with 11 policy and 8 payer participants, including: (1) payer representatives not prioritizing HPV vaccination specifically in incentive-driven clinic metrics; (2) policy representatives noting region-specific HPV vaccine policy options; (3) inconsistent motivation across policy/payer groups to improve HPV vaccination; (4) targeting of HPV vaccination in quality improvement initiatives suggested across policy/payer groups; and (5) COVID-19 pandemic viewed as both barrier and opportunity for HPV vaccination improvement across policy/payer groups. Discussion: Our findings indicate opportunities for incorporating policy and payer perspectives into HPV vaccine improvement processes. We identified a need to translate effective policy and payer strategies, such as pay-for-performance programs, to improve HPV vaccination within safety-net settings. COVID-19 vaccination strategies and community efforts create potential policy windows for expanding HPV vaccine awareness and access

Business · Environmental health · Family medicine · Safety net · Vaccination · Cervical Cancer and HPV Research · Head and Neck Cancer Studies · Medicine · Vaccine Coverage and Hesitancy · Virology